InvestorsHub Logo
Followers 16
Posts 1898
Boards Moderated 0
Alias Born 05/12/2016

Re: SPORT19 post# 85850

Monday, 04/15/2019 9:48:54 AM

Monday, April 15, 2019 9:48:54 AM

Post# of 140474
I think it's about the technology. How many indications is Senhance approved for? And how many systems have they sold, over what period of time?

I think additional indications will come very quickly; potential buyers will know that other indications have already been conducted under the IDE and surgeon feedback will be publicized by then.

I believe the speed of the sales ramp-up will be determined by Titan management, with willing buyers awaiting their turn in line. They will optimize the roll out with consideration to system availability, staffing and training, and customer needs. There will be places that are happy to start with Hyst and have their foot in the door when other indications are approved.

Of course funding will be needed, but as the program progresses through this year's milestones (and especially with initial FDA approval) share price will allow for any raises, if needed, to be substantially less dilutive.

And you should be more careful not to contradict yourself like that.



Message in reply to:

You should listen to the last conference call. MacNally said one of our predicate devices is non robotic...
Do you seriously think hospital administrators are going to buy this HOPING it gets approved for more indications? The reality is this is going to be a SLOW sales ramp up.
A number of centers will buy this out of the gate but it’s gonna take a lot of funding to keep this afloat.
Of course there can be an early buyout if approved. I think that’s why MacNally getting those low options so he can cut and run.